Company news

LTR Pharma Limited news in 2026

LTR Pharma Limited's news releases, calls and decks from 2026, newest first.

View company

Application for quotation of securities - LTP

November 6, 2026

Change of Director's Interest Notice - L Rodne

November 6, 2026

Change of Director's Interest Notice - J Chick

November 6, 2026

Change of Director's Interest Notice - M McGuire

November 6, 2026

Notification regarding unquoted securities - LTP

November 6, 2026

Notification regarding unquoted securities - LTP

November 6, 2026

Nick Bell Joins LTR Pharma as Strategic Adviser

November 3, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Results of Meeting

October 23, 2026

AGM Presentation

October 22, 2026

SPONTAN to be Evaluated in Pulmonary Arterial Hypertension

October 21, 2026

SPONTAN passes 2,000 dispensed units in Australia

October 20, 2026

Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.

October 7, 2026

Investor Webinar Presentation

October 5, 2026

First ROXUS Prescriptions Fulfilled in the United States

October 5, 2026

Clinical and Commercial Update - Investor Webinar

October 1, 2026

SPONTAN Phase II Final Results

September 30, 2026

Notice of Annual General Meeting/Proxy Form

September 22, 2026

Application for quotation of securities - LTP

September 11, 2026

Application for quotation of securities - LTP

September 4, 2026

Investor Presentation

September 2, 2026

LTR Expands Men's Health Portfolio with KYZATREX Pilot

August 31, 2026

FY26 Results Announcement

August 27, 2026

Appendix 4G and Corporate Governance Statement

August 27, 2026

Appendix 4E and Annual Report to Shareholders

August 27, 2026

SPONTAN Real-World Study Reports 93% Response

August 10, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 27, 2026

LTR Executes U.S. Commercial Agreement with Strive

July 19, 2026

LTR Executes Definitive U.S. Commercial Agreement with Shed

July 16, 2026

Response to ASX Aware Letter

June 15, 2026

LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS

June 10, 2026

LTR Secures First U.S. Commercial Agreement for ROXUS

June 8, 2026

SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations

May 4, 2026

SPONTAN Phase II data show rapid onset, support FDA pathway

April 30, 2026

SPONTAN Phase II Clinical Study Completes Recruitment

March 4, 2026

Appendix 4D and Half Yearly Report

February 25, 2026

SPONTAN Shows Positive Outcomes in Younger Men with ED

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 27, 2026

First Patients Dosed in SPONTAN Phase II Clinical Study

January 21, 2026

Decks in 2026